Stability of nifedipine in two oral suspensions stored at two temperatures

Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)

Volumn 42, Issue 6, 2002, Pages 865-867

  Nahata, Milap C ^a   Morosco, Richard S ^b   Willhite, Elizabeth A ^c  

^a Division of Pharmacy Practice and Administration   (United States)

^b University and Children s Hospital   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; METHYLCELLULOSE; NIFEDIPINE;

ARTICLE; CHEMISTRY; DRUG STABILITY; DRUG STORAGE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ORAL DRUG ADMINISTRATION; SUSPENSION; TEMPERATURE; TIME;

ADMINISTRATION, ORAL; ANTIHYPERTENSIVE AGENTS; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; DRUG STORAGE; METHYLCELLULOSE; NIFEDIPINE; SUSPENSIONS; TEMPERATURE; TIME FACTORS;

EID: 0036831333     PISSN: 10865802     EISSN: None     Source Type: Journal    
DOI: 10.1331/108658002762063709     Document Type: Article

References (7)

1. C.K. Taketomo J.K. Hodding D.M. Kraus Pediatric Dosage Handbook 7th ed. 2000 Lexi Comp, Inc Hudson, Ohio 687 688
2. Cardiac drugs—nifedipine Method 5120 Chromatography Sourcebook C500 2000 Alltech Associates, Inc Deerfield, Ill 457
3. M.C. Nahata T.F. Hipple Pediatric Drug Formulations 4th ed. 2000 Harvey Whitney Books Company Cincinnati, Ohio
4. Specific requirements on the content and format for labeling for human prescription drugs revision of “pediatric use” subsection in the labeling. 59 Federal Register 64240–0 (1994) (codified at 21 CFR § 291).
5. Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients, 21CFR § 201, 312, 314, 601.
6. V. Pai M.C. Nahata Need for extemporaneous formulations in pediatric patients J Pediatr Pharmacol Ther. 6 2001 107 119
7. M. Helin-Tanninen T. Naaranlahti K. Kontra K. Wallenius Enteral suspension of nifedipine for neonates. Part 1. Formulation of nifedipine suspension for hospital use J Clin Pharm Ther 26 2001 49 57